Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Phase II, Multicenter Clinical Study of Serplulimab Combined with First-Line Targeted Therapy and Chemotherapy with or Without Radiation in the First-Line Treatment of Advanced Colorectal Cancer

NCT06521866 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06521866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06521866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Phase II, Multicenter Clinical Study of Serplulimab Combined with First-Line Targeted Therapy and Chemotherapy with or Without Radiation in the First-Line Treatment of Advanced Colorectal Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2025
Completion date
August 1, 2027
Enrollment
208 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal carcinoma, immunotherapy